Intellipharmaceutics International Inc. (IPCI)

[declaes]

NEW SAarticle....

Wall Street Is Overlooking Intellipharmaceutics- CFO Shameze Rampertab Tells Us Why
Tuesday, July 29, 10:45 AM ET | About: IPCI

Trevor Lowenthal
Contributor to The Motley Fool, Seeking Alpha and Founding Contributor to TalkMarkets. Founder of KnowHow Tutors With emphasis on the biopharmaceutical industry, I focus my portfolio on undervalued opportunities. Through my position with Seeking Alpha, I hope to elucidate undervalued companies that are exploring revolutionary treatment modalities for a wide spectrum of rare and devastating medical conditions. I strive for an open, honest and insightful dialogue with expert and amateur readers alike. I appreciate your comments and encourage readers to follow me to stay updated on my newest stock ideas. I am happy to consult and/or collaborate on articles. Contact: [e-mail] or message me.
Summary

Intellipharmaceutics is an emerging pharmaceutical company listed on the Nasdaq.
It has a significant opportunity to market proprietary compounds within the controlled delivery space, namely Rexista oxycodone, which could be the best in class, abuse-deterrent opioid.
I conducted a conference call with Shameze Rampertab, Vice President of Finance and CFO of Intellipharmaceutics.